Roche strikes another China deal Read in browser

Thank you for reading, Test Researcher! basic Subscription UPGRADE

M Tue W Th F 13 October, 2026

Which ESMO readouts will shake up pipelines and shift clinical practice? Endpoints reporters sit down with oncology leaders to take stock of the evolving ecosystem and the new targets biopharma is chasing. Register now.

presented by Greater em­pa­thy, greater ef­fi­cien­cy: How pa­tient-first clin­i­cal de­vel­op­ment ben­e­fits all of us

news Roche's seventh China deal this year is a $1.2B obesity pact with an RNAi biotech Paragon spins out ninth biotech, sending cardiopulmonary drugs to Alaunos •  After $10.9B exit to AbbVie, Apogee execs join Paragon to scale its R&D, company creation engine Syndax's lung disease ambitions for Niktimvo end with a Phase 2 failure

Nov 12 12:30 pm ET From data to diagnostic: How AI is powering biomarker discovery sponsored by Guardant Health Nov 03 11:30 am ET Trust, not autonomy: Deploying agentic AI in GxP environments sponsored by Katalyze AI Nov 04 11:00 am ET Cutting through the noise: How biopharma is actually using AI to scale oncology research sponsored by Flatiron Health Oct 28 10:30 am ET The evolution of MRD: From molecular detection to clinical decisions sponsored by ABBOTT Oct 13 11:00 am ET Commercial excellence and AI - a ripple, wave or a tsunami sponsored by ZS Oct 15 1:00 pm ET Insights into Polycystic Kidney Disease: The Potential of Clinicogenomic Data sponsored by Natera Oct 20 11:00 am ET Intelligent oversight and orchestration: How mission control is redefining R&D decision-making sponsored by ZS Oct 21 11:00 am ET From prediction to decision: Digital twins and predictive modeling in clinical development sponsored by Flatiron Oct 22 11:00 am ET A new model for clinical research – Expanding community trial access sponsored by Parexel

Biopharma's balance of power is shifting, and in January, Endpoints journalists will press the people at the center of it on who's rising, who's falling and where the industry may land by the end of the decade. Join us at #JPM27 for exclusive conversations and interviews you won't get anywhere else. Save $200 on your all-access pass with Early Bird, or join us virtually for free.

Endpoints Pharma Merck reports mixed data for Lucentis competitor in diabetic macular edema Asahi Kasei lands approval for new HSV treatment Brent Saunders abruptly exits Bausch + Lomb, ending second stint as CEO

in case you missed it